BioMS Medical announces third quarter 20...(expenses related to the public companyli...)

Investment income earned on funds invested was $0.4 million for the three months ended September 30, 2007, the same amount that was earned for the three months ended September 30, 2006. For the nine months ended September 30, 2007, investment income was $1.3 million compared to $0.9 million for the nine months ended September 30, 2006. Investment income is earned from the short-term investment of cash reserves in low-risk term deposits and high-quality low-risk funds.

As at September 30, 2007, cash and short-term investments totaled $49.2 million as compared to $43.1 million at December 31, 2006. As at September 30, 2007, the Corporation had working capital of $45.9 million as compared to $37.4 million at December 31, 2006. Management estimates that the current working capital is sufficient for the Corporation to meet its obligations in respect of the currently initiated clinical trials through to the latter part of 2008.

As at November 14, 2007 there were 91,339,823 Class "A" common shares of the Company issued and outstanding.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This news release may contain certain forward-looking statements that reflect the current views and/or
'/>"/>